OLD Dominion Capital Management Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the company’s stock after selling 277 shares during the quarter. OLD Dominion Capital Management Inc.’s holdings in Johnson & Johnson were worth $791,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A lifted its position in Johnson & Johnson by 2.2% during the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after buying an additional 1,321 shares in the last quarter. Lynch & Associates IN lifted its position in Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after buying an additional 841 shares in the last quarter. Welch & Forbes LLC lifted its position in Johnson & Johnson by 0.9% during the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after buying an additional 6,730 shares in the last quarter. Oakbrook Investments LLC lifted its position in Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after buying an additional 9,375 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in Johnson & Johnson by 0.5% during the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after buying an additional 3,533 shares in the last quarter. Institutional investors and hedge funds own 65.61% of the company’s stock.
A number of equities analysts recently commented on the company. J P Morgan Chase & Co lifted their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Citigroup Inc. assumed coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. BMO Capital Markets reiterated a “positive” rating and set a $152.00 price objective (up previously from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average price target of $143.70.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the previous year, the business earned $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.45%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.